Wegovy, the new anti-obesity drug from Novo Nordisk, has officially launched in France, but access is limited to specific patients. The National Agency for the Safety of Medicines (ANSM) has set strict eligibility criteria, requiring a prescription from specialists in endocrinology, diabetology, or nutrition for initial treatment. Patients must have a body mass index (BMI) of 35 or higher and must have previously attempted nutritional support without success. Renewals can be managed by general practitioners.
The cost of Wegovy is a significant barrier, with prices ranging from 270 to 360 euros per month, currently not covered by health insurance in France. This presents challenges for lower-income individuals who are disproportionately affected by obesity, raising concerns about equitable access to this treatment.
Despite its high price, Wegovy is anticipated to have a substantial impact on weight loss, with clinical trials showing an average reduction of 15% body weight over 68 weeks. The drug has gained popularity in the U.S. and among celebrities, contributing to its high demand in France.
Novo Nordisk is actively seeking reimbursement options for Wegovy in France, having received a positive opinion for its reimbursement based on its effectiveness in reducing cardiovascular risks, which could expand access to more patients in the future.
